Allergan Shares Updated Data From Vision Loss Candidate Showing Significant Improvement In Near-Vision Reading

  • Allergan, a unit of AbbVie Inc ABBV, has announced new data, including the full results from the Phase 3 GEMINI 1 study of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for presbyopia.
  • Multiple data presentations were made at the 2021 ASCRS Annual Meeting.
  • Data demonstrated that AGN-190584 met both its primary and key secondary efficacy endpoints, with patients achieving near and intermediate vision gains. 
  • In addition, AGN-190584 showed no loss of distance vision, rapid onset of action, and sustained vision gains of up to six hours. 
  • Presbyopia is a progressive eye condition that makes it difficult to focus on things up close and affects most adults over 40. 
  • A statistically significant greater proportion of participants treated with AGN-190584 gained the ability to read three additional lines on a reading chart in low light, high contrast, at Day 30, Hour 3 (22.5%), and Hour 6 (9.7%) versus the vehicle. 
  • Additional endpoints evaluated showed that 75% of participants treated with AGN-190584 achieved at least 2-line improvement, and 93% of participants achieved over 20/40 vision in photopic (daylight) DCNVA. 
  • No treatment-emergent serious adverse events were observed in any AGN-190584 treated participants. 
  • The most common treatment-emergent non-serious adverse event in the AGN-190584 group was a headache. 
  • Most side effects were mild and transient, with only 1.2% of patients discontinuing due to adverse events.
  • Price Action: ABBV shares closed at $118.19 on Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!